Repare Common Stock Total Equity from 2010 to 2024

RPTX Stock  USD 2.81  0.16  5.39%   
Repare Therapeutics Common Stock Total Equity yearly trend continues to be fairly stable with very little volatility. Common Stock Total Equity is likely to outpace its year average in 2024. Common Stock Total Equity is the total value of common stock equity held by shareholders, representing their ownership interest in the company. View All Fundamentals
 
Common Stock Total Equity  
First Reported
2010-12-31
Previous Quarter
552.8 M
Current Value
580.4 M
Quarterly Volatility
245.3 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Repare Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Repare Therapeutics' main balance sheet or income statement drivers, such as Tax Provision of 2.8 M, Interest Income of 13.8 M or Depreciation And Amortization of 1.8 M, as well as many indicators such as Price To Sales Ratio of 5.71, Dividend Yield of 0.0 or PTB Ratio of 1.52. Repare financial statements analysis is a perfect complement when working with Repare Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Repare Therapeutics Correlation against competitors.
For more information on how to buy Repare Stock please use our How to Invest in Repare Therapeutics guide.

Latest Repare Therapeutics' Common Stock Total Equity Growth Pattern

Below is the plot of the Common Stock Total Equity of Repare Therapeutics over the last few years. It is the total value of common stock equity held by shareholders, representing their ownership interest in the company. Repare Therapeutics' Common Stock Total Equity historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Repare Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Common Stock Total Equity10 Years Trend
Slightly volatile
   Common Stock Total Equity   
       Timeline  

Repare Common Stock Total Equity Regression Statistics

Arithmetic Mean165,264,593
Geometric Mean78,883
Coefficient Of Variation148.45
Mean Deviation220,351,457
Median1,000.00
Standard Deviation245,336,669
Sample Variance60190.1T
Range580.4M
R-Value0.84
Mean Square Error19392.2T
R-Squared0.70
Significance0.000099
Slope45,925,487
Total Sum of Squares842661.1T

Repare Common Stock Total Equity History

2024580.4 M
2023552.8 M
2021480.7 M
2020384.3 M

About Repare Therapeutics Financial Statements

Repare Therapeutics investors use historical fundamental indicators, such as Repare Therapeutics' Common Stock Total Equity, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Repare Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Common Stock Total Equity552.8 M580.4 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Repare Stock Analysis

When running Repare Therapeutics' price analysis, check to measure Repare Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Repare Therapeutics is operating at the current time. Most of Repare Therapeutics' value examination focuses on studying past and present price action to predict the probability of Repare Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Repare Therapeutics' price. Additionally, you may evaluate how the addition of Repare Therapeutics to your portfolios can decrease your overall portfolio volatility.